Ossianix, Inc.

DUBLIN, Oct. 19, 2023 /PRNewswire/ -- The "Antibody Discovery Market: Focus on Services and Platforms - Distribution by Type of Service Offered, Antibody Discovery Method, Type of Antibody Generated, Nature of Antibody Generated, Therapeutic Areas and Key Geographies: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering. The global antibody discovery services and platforms market is poised for significant growth, with a projected value of over $1.6 billion in 2023 and a forecasted Compound Annual Growth Rate (CAGR) of 12.0% during the coming years. The market is driven by pharmaceutical companies' increasing reliance on outsourcing antibody discovery processes and the growing demand for targeted therapies. Streamlining Drug Development with Outsourcing The traditional drug development process is lengthy, spanning 10-15 years and involving investments of over $2 billion. Despite these efforts and investments, more than 90% of drug candidates fail in clinical trials. To streamline drug development, reduce timelines, and mitigate financial risks associated with failed trials, pharmaceutical companies are increasingly outsourcing their discovery-stage operations to specialized contract research organizations (CROs). Outsourcing allows companies to optimize resource utilization, save costs, and tap into a global network of scientific talent, ultimately enhancing the efficiency and success rate of bringing novel antibody-based therapeutics to market. Evolution of Monoclonal Antibodies Since the approval of the first monoclonal antibody-based therapy, Orthoclone OKT3, in 1986, monoclonal antibodies have become a versatile class of biopharmaceuticals. These antibodies have seen significant advancements in engineering, format diversification, and discovery methods. Over 160 monoclonal antibodies have been approved worldwide for the treatment of diseases such as cancer, chronic inflammatory diseases, infectious diseases, and cardiovascular diseases. Recent approvals include ELREXFIOT, TALVEYT, Rystiggo, COLUMVI, and EPKINLYT. Due to the complexities associated with discovering such antibodies, many firms are licensing and utilizing specialized antibody discovery platforms and technologies, driving the growth of the antibody discovery services and platforms market. Market Drivers: Biotech Advancements and Increasing Demand Key drivers of the global antibody discovery services and platforms market include recent advancements in biotechnology, a growing demand for targeted therapies, rising prevalence of chronic diseases, increased R&D expenditure in the pharmaceutical industry, and a growing trend of outsourcing antibody discovery. Collaborations between academic institutions and antibody discovery companies further contribute to market growth. Market Size and Segments The global market size for antibody discovery services and platforms is projected to grow at an annualized CAGR of 11.0% during the forecast period. The hit generation segment holds the largest market share, driven by its significance in R&D expenditure. In terms of the antibody discovery method, the hybridoma method is dominant, thanks to its capability to create immortalized cell lines for continuous antibody manufacturing. Regional Analysis: North America Leads North America currently captures nearly 40% of the market, driven by a rising interest in advanced antibody discovery platforms and increased outsourcing in the pharmaceutical industry. North America is anticipated to grow at a CAGR of 12% during the forecast period. Key Players and Recent Developments Key players in the antibody discovery services and platforms market include Ablexis, Antibody Solutions, ChemPartner, GenScript, Genmab, Harbour BioMed, ImmunoPrecise, Mabsilico, and more. Recent developments in the field include the launch of transgenic mouse-based antibody discovery platforms and initiatives to support the discovery of bispecific antibody formats. Recent Developments: In June 2023, AbTherx announced the launch of its transgenic mouse-based antibody discovery platform, AtlasT Mice. In June 2023, Sanyou Biopharmaceuticals, a China-based company, launched its Sanyou Super Trillion Common Light Chain Antibody Discovery Platform, which supports the discovery of bispecific antibody formats. In January 2023, IASO Biotherapeutics raised USD 75 million in a venture series C round, highlighting the increasing funding activity in the antibody drug discovery service and platform domain. In March 2023, Twist Bioscience announced the launch of its antibody discovery services under the Twist Biopharma Solutions subsidiary after acquiring Abveris, an antibody discovery CRO, in 2022. Key Topics Covered: 1. PREFACE 2. RESEARCH METHODOLOGY 3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS 4. EXECUTIVE SUMMARY 5. INTRODUCTION 6. ANTIBODY DISCOVERY: PROCESS AND METHODS 7. ANTIBODY DISCOVERY SERVICE PROVIDERS: MARKET LANDSCAPE 8. COMPANY COMPETITIVENESS ANALYSIS 9. COMPANY PROFILES: ANTIBODY DISCOVERY SERVICE PROVIDERS 10. ANTIBODY DISCOVERY TECHNOLOGIES: MARKET LANDSCAPE 11. TECHNOLOGY COMPETITIVENESS ANALYSIS 12. COMPANY PROFILES: ANTIBODY DISCOVERY PLATFORM PROVIDERS 13. PARTNERSHIPS AND COLLABORATIONS 14. FUNDING AND INVESTMENT ANALYSIS 15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES 16. GLOBAL ANTIBODY DISCOVERY SERVICES MARKET 17. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF SERVICE OFFERED 18. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF ANTIBODY DISCOVERY METHOD 19. ANTIBODY DISCOVERY SERVICES MARKET, BY NATURE OF ANTIBODY DISCOVERED 20. ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE OF THERAPEUTIC AREAS 21. ANTIBODY DISCOVERY SERVICES MARKET, BY KEY GEOGRAPHIES 22. GLOBAL ANTIBODY DISCOVERY TECHNOLOGIES MARKET 23. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY TYPE OF ANTIBODY DISCOVERED 24. ANTIBODY DISCOVERY TECHNOLOGIES MARKET, BY KEY GEOGRAPHIES 25. LICENSING DEAL STRUCTURE 26. SWOT ANALYSIS: ANTIBODY HUMANIZATION SERVICE PROVIDERS 27. CASE IN POINT: DRUG DISCOVERY PROCESSES OF TOP SELLING ANTIBODIES 28. FUTURE GROWTH OPPORTUNITIES IN ANTIBODY DISCOVERY 29. CONCLUSION 30. EXECUTIVE INSIGHTS 31. APPENDIX 1: TABULATED DATA 32. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION Companies Mentioned 2BScientific 3SBio AAT Bioquest Ab Initio Biotherapeutics Ab Studio ABBA Therapeutics AbBioSci Abbiotec AbbVie Abcalis Abcam AbCellera Abcentra (formerly CardioVax) Abcepta AbCheck Abclonal Abcore ABDYS Abeome Abexxa Biologics ABGENEX AbGenics Life Sciences Abilita Bio ABL Bio Ablexis Ablynx Abnova Abpro AbSano Absci Absea Biotechnology Absolute Antibody Abterra Biosciences AbTherx AbTis Abveris (Acquired by Twist Bioscience) AbVision Abwiz Bio Abzena Abzyme Therapeutics AC Immune Acceleron Pharma Accurus Biosciences AceMab Achaogen Aclys Bio ACROBiosystems ACYTE Biotech Adagene Adaptate Biotherapeutics ADC Therapeutics Adcentrx Therapeutics Adimab AdipoGen Life Sciences Administration for Strategic Preparedness and Response (ASPR) Aduro Biotech AffinityImmuno AFSBio Aganitha Agency for Science, Technology and Research Agenus Agro-Bio AIMM Therapeutics Aimmune Therapeutics Akeagen Akeso Akeso Biopharma Alacrita Alamar Biosciences Aldevron Alector Alexion AlivaMab Discovery Services Alligator Bioscience Allogene Therapeutics Alloy Therapeutics Almirall AlpalifeBio ALSA Ventures Alvaxa Biosciences (Acquired by Sensei Biotherapeutics) ALX Oncology Alytas Therapeutics Amerigo Scientific Amgen AMSBIO Analytics Engine AnaptysBio Angios Annoron Biotechnology Antengene Antibodies Incorporated Antibodies-online Antibody Analytics Antibody Design Labs Antibody Production Services (A division of Life Science Group) Antibody Solutions Antiverse AP Biosciences Apexigen APITBIO Applied Biological Materials Applied StemCell AprilBio Aptevo Therapeutics Aragen Life Sciences Aravive Arctoris Arcus Biosciences argenx Aridis Pharmaceuticals aRNAy Sciences Aro Biotherapeutics Aronora Arsanis Artizan Biosciences Arvinas ARVYS Proteins AskGene Pharma Astellas AstraZeneca aTen Therapeutics Atlantis Bioscience Atlas Venture Atreca ATUM Aureka Aurigene Pharmaceutical Services Autolus Therapeutics Automated Lab Solutions AvantGen Aviva Systems Biology AxioMx Axxora Bayer BBI Group BBI Solutions Beckman Coulter BeiGene BenevolentAI Berkeley Lights Betta Pharmaceuticals Bhami's Research Laboratories Bhat Bio-tech India Big Cypress Acquisition BigHat Biosciences Bill & Melinda Gates Foundation Bill & Melinda Gates Medical Research Institute Bio Bench BioArctic BioAtla BioBench Solutions Biochem Pharma BioClue (Acquired by ImmunoPrecise Antibodies) Bio-Connect Biocure Technology Biocytogen BioD BioDuro-Sundia Biogen BioHub International Trade Bioinborn Scientific Biointron BioInvent BioKey (Acquired by ImmunoPrecise Antibodies) Biologics International Biomolecular Discovery Services BioNTech Bioqube Ventures Bio-Rad Laboratories Biosion BioStrand (Acquired by ImmunoPrecise Antibodies) Biosynth Biotalys Bio-Techne Biotecnol BIOTEM BioTeZ Biotheus BioTickle BioVision BioXpress Therapeutics Bird Rock Bio Blue Sky BioServices (Acquired by LakePharma) BlueBird Bio Bluejay Therapeutics Boan Biotech Boehringer Ingelheim Bolt Biotherapeutics Boster Biological Technology Bristol Myers Squibb Broteio Pharma CALIXAR Cambridge Research Biochemicals CANbridge Pharmaceuticals Cancer Research UK Cantargia Capra Science Capralogics Caris Life Sciences Carterra CASI Pharmaceuticals Catalent Biologics Cayman Chemical CD ComputaBio CDI Laboratories Celexion Celgene Cell Signaling Technology Celltrion Celros Biotech Celsius Therapeutics Centre for Applied Medical Research Centers for Disease Control and Prevention Charles River ChemBio Discovery Solutions ChemPartner Cherry Biolabs Chia Tai Tianqing Pharmaceutical Chiome Bioscience Chipscreen Biosciences ChromoTek Chugai Pharmabody Research Chugai Pharmaceutical Cidara Therapeutics Cilag Citryll City of Hope Cizzle Biotechnology Clayton Biotechnologies Click Chemistry Tools Clinica Universidad de Navarra CliniSciences Columbia University Irving Medical Center Compass Therapeutics Context Therapeutics Coronavirus Immunotherapy Consortium Corvidia Therapeutics Cosmo Bio CP Qingdao Creative Bioarray Creative Biolabs Creative Biostructure Creative Diagnostics Crescendo Biologics Crystal Bioscience CSL Behring Cstone Pharmaceuticals CureVac Curia CUSABIO Cyclogenix Cygnus Technologies DAAN Biotherapeutics Daiichi Sankyo Dako Dana-Farber Cancer Institute Danaher DaTaMabs DBA Italia Deerfield Discovery and Development Denali Therapeutics DetaiBio Diagnostic BioSystems Diatheva Digital Proteomics Dingkang Biology discoveric bio Distributed Bio DJS Antibodies Dragonfly Therapeutics E2DG Eisai Elabscience Eli Lilly and Company Elpis Biopharmaceuticals Emergent BioSolutions Empirico e-nnovation Life Sciences ENPICOM Enthera Entos Pharmaceuticals Envigo EpimAb Biotherapeutics EQRx Erasmus MC Ethris Eureka Therapeutics Eurofins Discovery Everest Medicines Evitria Evotec EVQLV Exelixis ExeVir Bio Exiris exonbio Exscientia Faculta (Acquired by Prosci) FairJourney Biologics Faron Pharmaceuticals Ferring Pharmaceuticals FibroGen Five Prime Therapeutics Fluoroprobes Forty Seven Foundery Innovations Fred Hutchinson Cancer Center Frederick National Laboratory for Cancer Research French Institute of Health and Medical Research Frugi Biotechnology Funakoshi Fusion Antibodies Fusion Pharmaceuticals G&P Biosciences G.CLIPS BIOTECH Gator Bio Genagon Therapeutics Gene Techno Science GeneBeyond Genedata GeneFrontier GENEWIZ (Acquired by Azenta Life Sciences) GeneX India Bioscience Genmab Genome Institute of Singapore Genor Biopharma GenoSafe Genovac GenScript Genuv Gen-Y Biologics GigaGen Gilead Sciences Gladstone Institutes Glenmark Pharmaceuticals Glythera Gmax Biopharm Government of British Columbia Government of Canada Green Mountain Antibodies Grenoble Hospital GSK Gustave Roussy GV20 Therapeutics HaemaLogiX Hangzhou Qiantang River Electric Harbour Antibodies Harbour BioMed Harpoon Therapeutics HD Biosciences Helix BioPharma Jiangsu Hengrui Pharmaceuticals Henlix Biotech Heptares Therapeutics HI-Bio HiFiBiO Therapeutics Himalaya Therapeutics H-Immune Therapeutics (Acquired by HiFiBiO Therapeutics) HJB Holzel Diagnostika Handels Horizon Discovery Hualan Genetic Engineering Hubrecht Institute Humanigen Hummingbird Bioscience I&L Biosystems i2 Pharmaceuticals IAMA France IASO Biotherapeutics Ibex Biosciences iBio Icagen Icosagen IGEM Therapeutics IgGenix IGM Biosciences I-Mab Biopharma iMetabolic Biopharma Immatics Biotechnologies Immorna Immune Biosolutions Immune Pharmaceuticals Immunitas Therapeutics immunitoAI Immunochem ImmunoChina Pharmaceuticals ImmunoGenes Immunome Immunomic Therapeutics ImmunoPrecise Antibodies ImmunoQure Immusmol Immutep In-Cell-Art Incyte Indivumed InflaRx Inhibrx Innate Pharma InnoBation Bio Innovagen Innovative Targeting Solutions Innovent Inotiv InstaDeep Institute for Research in Biomedicine Intarcia Therapeutics (Acquired by i2o Therapeutics) Integral Molecular Integrated DNA Technologies International Livestock Research Institute Invenra Invetx IONTAS IRBM Isogenica Italian National Institute of Health ITBMed iTeos Therapeutics Janssen Jazz Pharmaceuticals Johnson & Johnson Innovation Jotbody Jounce Therapeutics Juno Therapeutics Junshi Biosciences Just Biotherapeutics JW Pharmaceuticals Kadmon Kairos Therapeutics KAKEN PHARMACEUTICAL Kanwhish Biotechnology KareBay Biochem Karolinska University Hospital Kemp Proteins KGbio Kite Pharma KMD Bioscience Kodiak Sciences KYinno Kymab Kyoritsuseiyaku Kyowa Kirin La Jolla Institute for Immunology LabGenius Labtoo LakePharma LamKap Bio LAMPIRE Biological Labs Lanier Biotherapeutics Lava Therapeutics Leadgene Biomedical Leading Biology Leads Biolabs LegoChem Biosciences Leica Microsystems LEO Pharma LG Chem LifeArc LifeTein Ligand Pharmaceuticals Light Chain Bioscience Lineage Cell Therapeutics Lonza Loxo Oncology Lunaphore Lundbeck Luye Pharma MAB Discovery MabGenesis Mablytics Mabpharm MAbSilico mAbsolve MabSpace Biosciences Mabtech MabVax Mabworks MacroGenics Magenta Therapeutics Maine Biotechnology Services Maravai LifeSciences Masaachusetts General Hospital Mass Biologics Maverick Therapeutics Beijing Mede Taikang Biotechnology MedAbome MedGenome Medicilon MedImmune Medix Biochemica MEDx MEMO Therapeutics Memorial Sloan Kettering Cancer Center Merck Merus Mila MI-mAbs Mithra Pharmaceuticals Mitsubishi Tanabe Pharma Corporation Moderna ModeX Therapeutics ModiQuest Molcure Molecular Devices Molecular Templates MolMed Mologic Moradec MorphoSys Mount Sinai MSD MSM Protein Technologies Mycenax Biotech Myrio Therapeutics Mythic Therapeutics Nanjing Chia-Tai Tianqing Pharmaceutical Company Nanocarry Therapeutics NanoCellect Biomedical NanoString Technologies National Cancer Institute National Research Council of Canada's Human Health Therapeutics Research Centre National, Heart, Lung, and Blood Institute NaturalAntibody Nautilus Systems NB Health Laboratory NBE Therapeutics Nelum NeoBiotechnologies NeoClone Neon Therapeutics neoX Biotech Neurimmune Nexum Nidus MB Technologies Nidus BioSciences Nkarta Nona BioSciences Nordic Society of Gynaecological Oncology Normunity North Dakota State University Northway Biotech NovaRock Biotherapeutics Novartis Novo Holdings Novo Nordisk Numab Therapeutics NYU Langone Health Oak BioSciences Oblique Therapeutics Olympic Protein Technologies OmniAb OncoC4 OncoOne OncoResponse Oncothyreon Onena Medicines Ono Pharmaceuticals Open Monoclonal Technology Optimeos Life Sciences OREGA Biotech OriCell OriGene Technologies OriMAbs Orion OSE Immunotherapeutics Ossianix Oxford Biomedica OXGENE Pandion Therapeutics Panoply Bio Paragon Therapeutics Pascal Biosciences Pediatric Brain Tumor Consortium Penn Medicine PerkinElmer Perseus Proteomics Pfizer pH Pharma Phanes Therapeutics PharmAbcine PharmAbs PharmaEssentia Innovation Research Center PharmaLegacy Pharmsynthez Pierre Fabre Pinteon Therapeutics Pioneering Medicines Pionyr Immunotherapeutics Potenza Therapeutics Precision Antibody Prellis Biologics ProMab Biotechnologies Prometheus Authors Prosci Protein Alternatives Proteogenix ProteoNic ProtTech Purdue Pharma Pure Biologics PX'Therapeutics QIMR Berghofer Medical Research Institute QoolAbs Quadira Biosciences Queen's University Rallybio Rapid Novor RayBiotech RD Biotech ReCentrics Biotechnology Regeneron Pharmaceuticals Resonant Therapeutics Retrogenix RevMab Biosciences Revolve Biotechnologies Rezolute Roche Rockland Immunochemicals RubrYc Therapeutics Rx Biosciences RxBiologics SAb Biotherapeutics Saccharo Salipro Biotech San Diego Biomedical Research Institute Sanders Tri-Institutional Therapeutics Discovery Institute Sanofi Sanyou Biopharmaceuticals Sartorius SBH Sciences Scandion Oncology Scotia Biologics Sea Lane Biotechnologies Selecxine Sema4 Sensei Biotherapeutics Serum Institute of India Servier Severance Hospital Sevion Therapeutics Shanghai Henlius Biotech Shanghai KangaBio Shanghai Pidu Biotechnology Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS Shire Sichuan Kelun-Biotech Biopharmaceutical Siegfried Holding Simcere Simon Fraser University Single Cell Technology Sino Biological Sinobioway Sinopharm SmartPharm Therapeutics Sorrento Therapeutics SOTIO SouthernBiotech Specialised Therapeutics Specifica Sphere Fluidics Stanford University Straterx Summit Therapeutics Sunshine Guojian Surface Oncology Surrozen Sutro Biopharma Suzhou Bright Scistar Biotechnology Company Syd Labs Symphogen Synaffix Synbio Technologies Syngene Synthelis Tachyon Therapeutics Takeda Tanabe Research Laboratories Tasgen Biotech (Acquried by I-Mab Biopharma) Tasly Biopharmaceuticals Taurus Biosciences TC BioPharm Technical University of Denmark Telesis Bio Telix Pharmaceuticals Tempus Labs TeneoBio TESARO Tetra Partner Network Tetragenetics Teva Pharmaceuticals TG Therapeutics The Antibody Company The Wistar Institute Theraclone Sciences Theranyx ThermoFisher Scientific Third Venture Biopharma ThromboGenics Tizona Therapeutics Tmunity Therapeutics Torch Biosciences TRACON Pharmaceuticals TRANSCENTA Transgene TRIANNI Tsinghua University Tubulis Twist Bioscience U.S. Naval Medical Research Unit No. 3 UCLA Technology Development Group Universiti Sains Malaysia University College London University of Manchester University of Oxford University of Pennsylvania University of Southampton University of Surrey University of Texas MD Anderson Cancer Center University of Tokyo University of Zurich U-Protein (Acquired by ImmunoPrecise Antibodies) Utrecht University Vaccinex ValenzaBio (Acquired by ACELYRIN) Vall d'Hebron Institute of Oncology Valneva VBI Vaccines VectorB2B venBio Partners VERAXA Biotech Vir Biotechnology ViralClear Pharmaceuticals Visterra Viva Biotech Voyager Therapeutics Washington University Washington University School of Medicine Westlake Pharmaceuticals Services Westlake Therapeutics Wisconsin Alumni Research Foundation Worg Pharmaceuticals WuXi AppTec WuXi Biologics WuXi STA Wyss Institute XBiotech xCella Biosciences X-Chem Xencor XOMA Y- Biologics Yale Cancer Center Yangyang YenZym Antibodies Yinuoke Ymmunobio YUMAB Yurogen Biosystems Zai Lab Zebra Biologics Zhejiang Doer Biologics Zhejiang Teruisi Biopharmaceuticals Zoetis ZoonBio Biotechnology Zumutor Biologics Zydus Zymeworks For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Two highly experienced industry executives who bring a wealth of leadership and drug development experienceLONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023. “Both Mike and Scott are highly experienced industry executives who bring a wealth of leadership and drug development experience, and they will be an asset to our Board of Directors,” said Professor Amit Nathwani, Founder and CEO of NovalGen. “NovalGen is at a transformational stage in its development as we progress our lead product through the clinic as well as drive our pre-clinical programmes, including our first-in-class half-life extended T cell engager targeting ROR-1 with autoregulation capability, which demonstrates the inherent value in both our pipeline and our technology base.” Dr Michael Owen has worked in biomedical research, and in the pharmaceutical and biotechnology industries for over 40 years. He currently serves as a director on four boards. He is the Chairman of Ossianix Inc, a privately held biotechnology company, and is also on the boards of Zealand Pharma A/S, ReNeuron plc and Sareum Holdings plc. Dr Owen is also an advisor to several Venture Capital LPs and is Chairman of Avacta plc’s SABs. Prior to board services, Dr Owen co-founded and served as the first CSO of Kymab Ltd, a biopharmaceutical company recently acquired by Sanofi. Prior to co-founding Kymab, he worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D. Prior to joining the Pharma industry, Dr Owen was a Principal Scientist at the ICRF London laboratories (now CRUK) where he was noted for his work on lymphocyte development and on the molecular basis of diversity in the adaptive immune system. He received a BA degree from Oxford University and a PhD from Cambridge University. He was elected a member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences. Mr Scott Clarke brings more than 25 years of experience in the biotechnology and pharmaceutical industry. He is currently the CEO of Ambagon Therapeutics, and serves on the board of Trishula Therapeutics, where he was previously CEO. Prior to that, Mr Clarke was CEO of Tizona Therapeutics. Under his leadership, Tizona’s two lead programs advanced into clinic, and the company built out its preclinical portfolio, culminating in the spinout of Tizona’s lead program into Trishula and Gilead’s acquisition of rights to the rest of Tizona’s pipeline for $300 million up front and $1.25 billion in milestones. Prior to Tizona, Mr Clark was the Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering at Roche. Earlier in his career, he held senior roles at BioMarin, including the Senior Vice President of Product Development, responsible for advancing its portfolio of clinical and late preclinical product candidates through approval. He holds a BS in Chemical Engineering from the University of California, Berkeley, an MSc in Biotechnology at Northwestern University, and an MBA from London Business School. Further informationJW CommunicationsJulia WilsonTel. +44 (0) 7818 430877Email: juliawilsonuk@gmail.com About NovalGenNovalGen is a privately held clinical stage immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer, with the aim of creating life-saving new treatments for people with cancer. Alongside this, we are building out our auto-regulation platform that can be applied to a range of therapeutic indications outside of oncology, such as haematology as well as other immunotherapy indications, including cell-based therapies such as Chimeric Antigen Receptors (CAR-Ts). Our dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated products tailored to the needs of the patient. The company’s lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematologic malignancies and solid tumors using our breakthrough bispecifics technology.

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023. “Both Mike and Scott are highly experienced industry executives who bring a wealth of leadership and drug development experience, and they will be an asset to our Board of Directors,” said Professor Amit Nathwani, Founder and CEO of NovalGen. “NovalGen is at a transformational stage in its development as we progress our lead product through the clinic as well as drive our pre-clinical programmes, including our first-in-class half-life extended T cell engager targeting ROR-1 with autoregulation capability, which demonstrates the inherent value in both our pipeline and our technology base.” Dr Michael Owen has worked in biomedical research, and in the pharmaceutical and biotechnology industries for over 40 years. He currently serves as a director on four boards. He is the Chairman of Ossianix Inc, a privately held biotechnology company, and is also on the boards of Zealand Pharma A/S, ReNeuron plc and Sareum Holdings plc. Dr Owen is also an advisor to several Venture Capital LPs and is Chairman of Avacta plc’s SABs. Prior to board services, Dr Owen co-founded and served as the first CSO of Kymab Ltd, a biopharmaceutical company recently acquired by Sanofi. Prior to co-founding Kymab, he worked for GSK where he was SVP and Head of Research for Biopharmaceuticals R&D. Prior to joining the Pharma industry, Dr Owen was a Principal Scientist at the ICRF London laboratories (now CRUK) where he was noted for his work on lymphocyte development and on the molecular basis of diversity in the adaptive immune system. He received a BA degree from Oxford University and a PhD from Cambridge University. He was elected a member of the European Molecular Biology Organisation and a Fellow of the Academy of Medical Sciences. Mr Scott Clarke brings more than 25 years of experience in the biotechnology and pharmaceutical industry. He is currently the CEO of Ambagon Therapeutics, and serves on the board of Trishula Therapeutics, where he was previously CEO. Prior to that, Mr Clarke was CEO of Tizona Therapeutics. Under his leadership, Tizona’s two lead programs advanced into clinic, and the company built out its preclinical portfolio, culminating in the spinout of Tizona’s lead program into Trishula and Gilead’s acquisition of rights to the rest of Tizona’s pipeline for $300 million up front and $1.25 billion in milestones. Prior to Tizona, Mr Clark was the Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering at Roche. Earlier in his career, he held senior roles at BioMarin, including the Senior Vice President of Product Development, responsible for advancing its portfolio of clinical and late preclinical product candidates through approval. He holds a BS in Chemical Engineering from the University of California, Berkeley, an MSc in Biotechnology at Northwestern University, and an MBA from London Business School. Further information JW Communications Julia Wilson Tel. +44 (0) 7818 430877 Email: juliawilsonuk@gmail.com About NovalGen NovalGen is a privately held clinical stage immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer, with the aim of creating life-saving new treatments for people with cancer. Alongside this, we are building out our auto-regulation platform that can be applied to a range of therapeutic indications outside of oncology, such as haematology as well as other immunotherapy indications, including cell-based therapies such as Chimeric Antigen Receptors (CAR-Ts). Our dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated products tailored to the needs of the patient. The company’s lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematologic malignancies and solid tumors using our breakthrough bispecifics technology.